Market Overview

Vetr Upgrades Alnylam On News Of Streamed Press Conference

Vetr Upgrades Alnylam On News Of Streamed Press Conference
Related ALNY
Benzinga's Top Upgrades, Downgrades For November 9, 2017
The Market In 5 Minutes: Adidas, Jobless Claims, And More
A Look at Alnylam Pharmaceuticals' Rolling NDA (GuruFocus)

On Friday, the Vetr crowd upgraded their rating for Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) from its previous position at 1 star (Strong Sell) issued 88 days ago, to 4.5 star (Strong Buy). Crowd sentiment for the stock is edging positive with 66 percent of Vetr user ratings bullish.

The massive upgrade for Alnylam arrives on the same day the company announced it would livestream its R&D day press conference to investors. At the recent American Society of Hematology meeting in San Diego, the company revealed positive results in early tests of fitusiran, an experimental drug used to treat the effects of hemophilia.

Share price in Anylam enjoyed a healthy 6.6 percent jump early in the trading day on December 9. By 2 p.m. that same day, the stock had settled at $42.25.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $49.75, which is still far below the average analyst price of $70.13. Less than 2 percent of Vetr users are holding ALNY in their watch-lists.

At last check, Alnylam shares were up 3.54 percent at $42.25.

Latest Ratings for ALNY

Nov 2017Morgan StanleyMaintainsEqual-Weight
Nov 2017JP MorganUpgradesNeutralOverweight
Nov 2017BarclaysMaintainsOverweight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: American Society of HematologyBiotech Upgrades Health Care Crowdsourcing Events Markets Analyst Ratings


Related Articles (ALNY)

View Comments and Join the Discussion!

Partner Center